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Abstract 
The conventional interpretation of cancer, summarized in the unified genetic theory of 
carcinogenesis, assumes that the malignant cell is the anatomical and physiological 
unit of cancer. This assumption means that any evolutionary increase in the number of 
cells (and thus body size) should lead to a higher tumor incidence since the population 
at risk is higher. However, the available data fail to support this prediction: most 
animals, in particular most mammals, exhibiting wide differences in body size and 
lifespan, from the mouse to the blue whale, display a roughly similar tumor incidence.  
This unexpected lack of correlation between body size, lifespan and cancer is usually 
called Peto’s paradox and it has intrigued theoretical oncologists for decades. 
 
In this essay, we attempt to offer a putative explanation of this paradox based on the 
notion that the unit at risk of carcinogenesis is actually the tissue or organ rather than 
the individual cell. In turn, this notion is based on a different interpretation of 
neoplastic diseases that we proposed some years ago and that has been called the 
hypothesis of the biological sense of cancer.  
 
This hypothesis was based on the observation that throughout the animal kingdom, 
cancer seems to arise only in organs and tissues (or parts of them) that have 
experienced a significant decrease in the regenerative ability, and this would occur 
when a critical proportion of their cells have partially or wholly lost that capacity. In 
such a case, if an organism or an organ were x times larger than another one, the 
probability that its regenerative capacity is critically diminished would be x times 
lower, because an x times greater number of cells would have to be affected to 
depress that capacity. This lower probability would balance the proportionally higher 
number of their cells that could be transformed and this would explain why the blue 
whale displays no greater risk of developing cancer than the mouse by unit of time. 
However, since big animals tend to live y times longer than small ones, it remains to 
explain why both animals may display a similar tumor incidence by lifespan. The 
concept of mass-specific basal metabolic rate (msBMR) can account for this problem 
since msBMR diminishes with body weight as much as lifespan increases meaning that 
the time for individual cells to get both the natural decline in regenerative ability and 
potential neoplastic mutations should be, in the big animal, y times slower than in the 
small one. This could explain why the tumor incidence in blue whales along their long 
lifespan may be not higher than that observed in mice along their short life.  
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A “unified genetic theory of carcinogenesis” 
Since 1863, when Virchow extended his aphorism omnis cellula e cellula to include 
cancer cells, many researchers have proposed  different theories aimed to understand 
the nature of cancer and to answer the question of how tumors appear to begin with 
[1-3]. Since the late1970, different alterations in cellular genes as well as in several 
intracellular transducing signaling pathways have been identified in cancer cells, and 
on this basis a unified genetic theory of carcinogenesis has been advanced [4-9]. 
 
This “theory” states that cancer starts and ends with the malignant cell, in which 
genetic changes lead to constitutive activation of some genes (oncogenes) and/or 
inactivation of others (anti-oncogenes or tumor suppressor genes) allowing cells to 
evade the mechanisms controlling their proliferation. These genetic changes would 
define the molecular and cellular attributes of the cancer cell, which, in turn, should be 
the target of specific therapies against cancer. This theory has the particular merit of 
unifying through an immediate common pathway the numerous different mediators 
that cause cancer, such as chemicals, radiation, viruses, etc. However, it has some 
theoretical difficulties, which have been addressed by certain authors [10-13] who 
have also emphasized that – apart from some particular advances in targeted 
molecular therapies against certain tumors [14] - cancer remains a major cause of 
morbidity and mortality, despite the explosive development of our knowledge about 
the molecular mechanisms associated with the control of cell cycle and survival [15-
17]. In fact, if all cells in an organism have roughly equal possibilities of oncogene 
activation and/or tumor-suppressor gene inactivation, then, all else being equal, the 
number of cells susceptible to transformation should scale with body size, implying 
that very large animals such as rhinoceros, elephants and whales should be much more 
prone to cancer than very small ones, such as mice, since the cell population at risk is 
greater by several orders of magnitude. However, available data fail to support this 
prediction [18-20]. The unexpected lack of correlation between body size and cancer 
risk across species has been dubbed Peto’s paradox, since the statistical 
epidemiologist, Richard Peto, made this observation in 1977 [21]. Of course, this and 
other theoretical difficulties and the persistent failure in treating cancer do not 
necessarily imply that the “unified genetic theory of carcinogenesis” is incorrect. 
However, they encourage us to consider other possibilities. 
 
The hypothesis of the basic biological sense of cancer 
Some years ago, in an attempt to explore other theoretical approaches to cancer, we 
proposed [22, 23], - on the basis of ideas advanced by Prehn, Zajicek, Bissell, 
Sonnenschein and Soto among others [24-28] – the hypothesis of the biological sense 
of cancer.  
 
This hypothesis is based on the observation that throughout the animal kingdom, 
cancer is rarely – if ever – induced in organs or tissues displaying an efficient reparative 
or regenerative mechanism, "efficient" meaning the ability of organs and tissues to 
regenerate numerically and functionally. In effect, when these mechanisms remain 
fairly efficient throughout life – even under the action of putative noxious agents – as 
they do in animals displaying strong regenerative ability  - "strong" meaning the ability 
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to regenerate complex structures such as a whole limb or large regions of the body - 
cancer never (or almost never) occurs [29-41] (FIGURE 1).  
 
On the other hand, when the reparative mechanisms remain efficient only during 
youth – and even during youth, some noxious agents can deplete them – as they do in 
animals displaying weak regenerative ability - "weak" meaning the ability to repair or 
regenerate only relatively simple structures, as in compensatory hyperplasia of the 
liver, skin regeneration, etc. - cancer occurs mainly in aging individuals and also in 
injured organs from young individuals that may have experienced a significant decline 
of their regenerative ability because of the action of those noxious agents [22-24, 30, 
33, 34, 42-61] (FIGURE 1). 
 
 
 
FIGURE 1: General relationship between regenerative capacity and tumor incidence among the 
major metazoa groups.  
 
According to this interpretation, the origin of cancer could be envisaged as follows: 
when an organism has efficient regenerative mechanisms, cancer would not be 
produced. However, when an organism becomes aged - or is affected by noxious 
agents - and its regenerative ability declines progressively [58, 62], any injury causing 
loss of cells or diminished cellular function cannot be adequately compensated by 
cellular division. In consequence, the original size and function of the organ cannot be 
restored. We suggest that this situation induces a "crisis", which, through putative 
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danger signals resulting from retardation of tissue repair and functional compromise, 
could create an environment capable of promoting some degree of variability in the 
remaining cells of the injured organ that do not exhibit efficient reparative abilities. 
The outcome of this situation would be the emergence of some genetically and/or 
epigenetically modified cell variants. Most of these would still lack the ability to 
respond adequately to the organ demand, but sooner or later a variant bearing that 
mitotic ability would emerge by chance. This new variant would begin to divide; and if 
it were poorly functional or non-functional, the organ would be numerically but not 
functionally restored. In consequence, it would not score the regeneration as effective 
and it would continue to send mitotic signals to restore the lost or diminished organ 
function. As a result, the new variant would grow over and over and the outcome 
would be a tumor.  
 
Injury, development and cancer 
Many authors have highlighted the critical importance of injury in the development of 
cancer [60, 63-71], and the idea that cancer actually behaves as a wound healing 
process has been suggested by Dvorak [72-74]. On the other hand, cellular 
heterogeneity, and a genomic instability phase during stages of high-grade dysplasia 
prior to the acquisition of a frankly malignant phenotype, are two well-documented 
(though so far unexplained) phenomena [62, 75-77]. Similarly, well-documented are 
the picture of a tumor arising in a tissue surrounded by "normal" arrested and/or 
senescent cells, and the existence of factors involved in organ and tissue regeneration 
or produced directly by senescent cells that alter the local tissue microenvironment 
and that contribute, enhance or are necessary for tumor growth [26, 65, 78-80]. 
Furthermore, the induction of cell variability in aged organs associated with both an 
increased cell-to-cell transcriptional variability and an increased rate of mutations has 
also been recently demonstrated. In effect, Martínez-Jiménez et al [81] explored how 
natural aging impacts transcriptional dynamics using single cell RNA sequencing of un-
stimulated and stimulated naïve and effector memory CD4+T cells from young and old 
mice from two divergent species. They demonstrated that in young animals, 
immunological activation drives a conserved transcriptomic switch characterized by a 
strong up regulation of a core activation program coupled with a decrease in cellular 
variability. On the other hand, aging perturbed the activation of this core program and 
increased the cell-to-cell transcriptional heterogeneity in both divergent species [81]. 
In the same way, Ban and Kai suggested that replicative stress after irradiation 
accelerates the ageing of hematopoietic stem cells and that the ageing-related decline 
of mechanisms of DNA repair could increase the rates of spontaneous mutations [82].    
 
In summary, the hypothesis of the biological sense of cancer does not consider cancer 
an autonomous entity disobeying the mechanisms controlling cell proliferation, but 
one dependent on a reparative signal originating in the particular environment of an 
injured organ or tissue with diminished reparative ability. According to this 
interpretation, cancer would have a profound biological sense: it would eventually be 
the ultimate attempt to restore organ functions and structures that have been lost or 
altered by aging or noxious environmental agents. However, unlike normal structures, 
cancer would have no physiological value, because the usually poor or non-functional 
nature of its cells would make their reparative task unattainable.  
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Dependency of cancer on reparative processes 
Our suggestion that a tumor cell is not autonomous, but dependent on a reparative or 
regenerative signal originating in an "aged" organ or tissue seems heretical, because it 
contradicts the classical definition of Ewing ("A neoplasm is an autonomous, or 
relatively autonomous, growth of tissue"), which has guided cancer research for the 
last 70 or more years [83]. However, closer examination of Ewing's proposition reveals 
that it is a postulate rather than a true definition. First, pathologists do not use it as an 
operational tool to diagnose the presence of a tumor; in fact, "the means to diagnose 
cancer have not changed that much since"... the 19th century, "when pathologists 
began describing the histological pattern of tumors using the light microscope" [84]. 
Second, if nobody knows exactly what the mechanisms control normal cell 
proliferation [84], how can anyone be absolutely sure that cancer cells are disobeying 
those mechanisms? Many years ago, Dr. Joseph Aub suggested that the "ugly word 
autonomy” be dropped, because, while one can prove dependency, one can never be 
certain of autonomy [85]. 
 
 
Peto’s paradox: the riddle of the blue whale and the mouse 
The unified genetic theory of carcinogenesis postulates the idea that the malignant cell 
is the physiological and anatomical unit of cancer disease. Implicit in this contention is 
the assumption that the probability of origin of an aberrant, neoplastic cell lineage is 
the same per unit of cell population, regardless of species or cell type concerned. 
 
However, this assumption evokes one of the most intriguing riddles in cancer research, 
which remains unsolved. This riddle, stated by Dawe [31] and later by Peto [21, 86] 
many years ago, asks: "Why don't extremely large animals develop neoplasms with a 
much higher incidence than very small ones since the cell population at risk is greater 
by several orders of magnitude?" As an extreme example, let us consider the blue 
whale and the mouse. "If one takes the weight of the mouse as 30 g and that of the 
blue whale as 100 tons the whale is equivalent to 3,333,333 mice. Then, if one 
accounts for differences of lifespan (80 years for the blue whale, 2 years for the 
mouse, the ratio of weight-year units per whale to weight-year units per mouse is 
about 133,333,333" [31]. We should therefore expect the blue whale to develop 
neoplasms about 3 × 106 times and 130 × 106 times more often than the mouse per 
unit time and per lifespan, respectively. Since about 25% [range 9.5-40%] of wild mice 
kept under laboratory observation develop spontaneous malignant neoplasms during 
their lives [87-89], we should expect each blue whale to develop about 33 × 106 
malignant neoplasms per lifespan (FIGURE 2). It is clear that these expectations do not 
match reality: the incidence of cancer in whales, as well as in most groups of animals 
that develop cancer, including most mammals, is roughly similar to that in mice [18, 
19, 89, 90]. Actually, the incidence of cancer in the blue whale as well as in other large 
cetaceous seems to be even lower than that observed in most common mammals [91, 
92]. Similar considerations could be made concerning benign tumors. Therefore, the 
incidence of neoplasms, either malignant or benign, is not a simple function of 
protoplasm cell mass at risk per unit time.  
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FIGURE 2: Relative size of mouse (about 30 g), rhinoceros (about 2 tons) and blue whale (about 
100 tons) and theoretical influence that size of whole body, organ or tissue would have on 
tumor incidence per unit time on the assumption that the individual cell in an organ or tissue is 
the unit at risk of carcinogenesis. We have arbitrarily assumed that a carcinogenic mutation 
occurs at a rate of 1 per 20 cells units per unit time (tumor cells are identified with a mark 
inside the cell) and in consequence, animals with 2, 10 and 100 cells should develop, 
respectively, 1 neoplasm in every 10 animals, 2 neoplasms in every 4 animals and 5 neoplasms 
per animal, per unit time. The correspondence between animals (mouse, rhinoceros and blue 
whale) and number of cells (2, 10 and 100, respectively) is only illustrative. The figure was 
inspired in Dawe (quotation 31). 
 
 
Some ad hoc hypotheses have been invoked to account for this fact on the assumption 
that the individual cell in an organ or tissue is the unit at risk of carcinogenesis. For 
example, the animal fat depots might sequester fat-soluble carcinogens with efficiency 
proportional to animal's size and thereby proportionately diminish the exposure of 
other tissues. Other putative explanations hold that the evolution has equipped larger 
animals with extra tumor suppressor genes or with efficient defenses against cancer 
that could be proportional to animal size, such as mechanisms of DNA repair, cellular 
resistance to mutagenic activation of putative carcinogens, immunological 
surveillance, etc. [93-97]. However, these invoked mechanisms remain largely 
undemonstrated as general rules and in fact there is evidence that argues against 
some of these possibilities: for example, numerous studies on DNA repair allele 
polymorphisms have failed to provide any evidence of association with cancer risk 
[93]. 
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Is cancer a disorder of the individual cell? 
On the contrary, the hypothesis of cancer that we present in this essay could offer, at 
least in principle, a relatively easy solution of the riddle by assuming that the true basic 
unit at risk of carcinogenesis is the tissue or organ as a whole rather than the individual 
cell. In effect, according to this hypothesis, cancer originates in organs or tissues that 
display a significant decline of their regenerative capacities, and this would occur when 
a critical proportion of their cells have partially or wholly lost that capacity. In such a 
case, if an organ were x times larger than another one, the probability that its 
regenerative capacity is critically diminished would be x times lower, because an x 
times greater number of cells would have to be affected to depress that capacity. This 
lower probability would balance the proportionally higher number of their cells that 
could be transformed. As a result, if the unit at risk is, for example, one liver rather 
than 109 (mouse) as opposed to 3 × 1015 (blue whale) liver cells, then the whale will be 
at no greater risk of developing liver cancer than the mouse or any other animal with 
an equally efficient defense mechanism against cancer. A similar conclusion can be 
attained if the true basic unit at risk of carcinogenesis is a part of a tissue or organ 
rather than the tissue or organ as a whole.  
 
However, this interpretation may be not the whole story. In effect, it can explain the 
fact that animals with extremely different body sizes exhibit similar rates of tumor 
incidence by unit of time but the whole story also demands to explain a similar tumor 
incidence by unit of lifespan. In effect, in the case of the blue whale and the mouse our 
hypothesis may account for the fact that the blue whale has not a higher tumor 
incidence than that of the mouse by unit time, for example during the mouse’s 
lifespan, that is, 2 years. However, the blue whale lives 40 times more than the mouse 
(ratio lifespan of blue whale/ lifespan of mouse = 80/2 years = 40) and in consequence, 
the blue whale should, even accepting our hypothesis, develop 40 times more cancers 
during its life than the mouse. 
 
Metabolism and cellular activity 
The concept of basal metabolic rate (BMR) can be a useful tool to account for this 
problem. BMR is the rate of energy expenditure per unit time by endothermic animals 
at rest and accounts for about 60-70% of the daily caloric expenditure by individuals. 
Large animals have higher total BMR than smaller ones but the BMR at the cellular 
level (mass-specific BMR or msBMR) is much lower. In effect, according to the Max 
Kleiber’s law [98, 99], msBMR diminishes with body weight according to a 
mathematical principle called quarter-power scaling. For example, a cat that is 100 
times more massive than the mouse, displays a msBMR about 1001/4 (= 3.2) times 
lower than that of mouse. In the same way, the blue whale, that is about 3 × 106 times 
more massive than the mouse, displays a msBMR that is approximately equal to (3 × 
106)1/4  (about 40) times lower than that exhibited by the mouse. The reduction of 
msBMR with increased body size has been demonstrated in vivo. Some years ago, 
Wheatley and Clegg [100] suggested that this reduction is associated with the rate of 
delivery of both essential nutrients to cells and substrates to enzymes at the 
intracellular level, in the space of the organism, and that this effect should be absent 
under culture conditions, when the cells are removed from the influence of the body. 
This prediction was confirmed some years later by Brown et al. [101] who 
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demonstrated that neither metabolic rate nor the maximal activities of key enzymes of 
oxidative or anaerobic metabolism scaled significantly with donor body mass in 
cultured cells, indicating the absence of intrinsic, species-specific, cellular metabolic 
rate set points. 
 
Metabolism generates oxygen radicals that are considered to contribute to cellular 
aging as well as to potential oncogenic mutations [102, 103]. In consequence, the blue 
whale that exhibits a msBMR about 40 times lower than that of mouse should age 
about 40 times slower than the mouse and in consequence the time for individual cells 
to get the natural decline in regenerative ability observed with aging and the time to 
get potential neoplastic mutations should be, in the blue whale, 40 times slower than 
in the mouse. Taking into account that the ratio between lifespan of blue whale and 
mouse is really 40, then, we could explain why the tumor incidence in the blue whales 
along their long lifespan (80 years) may be not higher to that observed in mice along 
their short life (2 years).  
 
In summary, considering the hypothesis that cancer originates only in organs or tissues 
(or parts of them) that display a significant decline of their regenerative capacities 
together with the notion that the msBMR diminishes according to the quarter-power 
scaling, we can understand why the blue whale may not display a higher tumor 
incidence than that of the mouse, by unit of lifespan, that was what we wanted to 
demonstrate.  
 
This reasoning may be extended to most mammals exhibiting widely differences in 
body size and lifespan that range over nine orders of magnitude and 80 times, 
respectively [20, 89, 91, 104-116]. In effect, as shown in TABLE 1, the real incidence of 
cancer observed in more than forty different mammal species is, in all cases, strikingly 
lower than that predicted by assuming the individual cell as the unit of carcinogenesis, 
either considering cells of all species displaying similar or different msBMR. This 
difference between theory and reality tends to become astronomical as larger animals 
are considered.  
 
Towards a synthesis of these ideas 
In contrast, the real cancer incidence is, in most cases, very similar to that predicted by 
assuming the organ (or part of it) as the unit of carcinogenesis especially if we include 
into the hypothesis, the concept that msBMR decreases progressively as body mass 
increases, according to Kleiber’s law.  
 
Exceptional cases that do not fit completely to the general scheme described above, 
such as the elephant, the bowhead whale or the naked mole rat that display a 
significantly lower tumor incidence than that observed in most mammals, might also 
be understood by incorporating to the general scheme, the existence of particular 
mechanisms aimed to allow these animals to preserve the organ integrity and/or their 
regenerative ability quite efficiently throughout their lives. In fact, powerful 
mechanisms that protect from DNA damage, as invoked to be acting in elephants and 
bowhead whales, have been associated with protection against tissue damage [20, 
117, 118]. Similarly, different studies have suggested that the high-molecular-mass 
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Hyaluron secreted by naked mole rat’s cells, as well as other mechanisms, would 
protect these animals against stressors and prevent oxidative damage accrual and the 
translation of these potentially high levels of damage into a decline in normal function 
[110, 119,120]. Another two exceptions could be the blue whale, whose cancer 
incidence seems to be modestly lower than that of the mouse, and the human being. 
Actually, the human does not display a lower tumor incidence than most mammals but 
the predicted value - even considering the organ as unit of carcinogenesis and the real 
msBMR of our species - is significantly higher than the observed tumor incidence. This 
difference can be attributed to the fact that the predicted value is dependent to the 
lifespan of each species and the human displays a lifespan that is many times longer 
than that expected according to its mass-specific BMR.  
 
Cancer as a disorder of cellular society 
The idea that cancer is an organ or tissue disease rather than a cellular one has been 
advocated by Waddington, Smithers and others many years ago [2, 121] and, more 
recently, by the group of Sonnenschein and Soto with their tissue organization field 
theory (TOFT) of cancer [84, 122]. In agreement with this interpretation, Sigston and 
Williams [123] have recently proposed the idea that cancer may be the emergence of a 
new ‘system’ arising from the tissue components of a functional tissue unit or part that 
has experienced an alteration of its normal self-organization arrangement and 
function. 
  
The notion that other diseases – beyond cancer – may also be organ or tissue-based 
pathologies rather than cellular ones, is supported, for example, by the interpretation 
of rheumatoid arthritis advocated by Reines [124] in which this syndrome is considered 
the clinical manifestation of an underlying attempt to regenerate damaged or aged 
cartilage and sub-chrondal bone in an adult organism.  
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